Early Rhythm Control Beneficial in Patients With AF and Heart Failure
Researchers determined the effects of early rhythm control therapy in patients diagnosed with atrial fibrillation with signs and symptoms of heart failure.
Atrial Fibrillation
Promises and Pitfalls of Wearable Devices for Atrial Fibrillation Detection Evaluated
Using photoplethysmography (PPG) embedded in a smartwatch or wristband, patients can take an ECG with the tap of a button.
AHA Releases Scientific Statement on Sleep-Disordered Breathing and Cardiovascular Disease
The AHA outlines screening, diagnosis, and treatment recommendations for obstructive sleep apnea and CV complications tied to the sleep disorder.
Dysrhythmias in Patients With COVID-19
Sinus tachycardia is the most commonly reported dysrhythmia in patients with COVID-19 disease.
New DOAC Users Had Lower Risks for Ischemic Stroke, Major Bleeding vs New Warfarin Users
Study authors assessed the effectiveness and safety of DOACs compared with warfarin in patients with valvular atrial fibrillation.
Marine Omega-3 Fatty Acid, Vitamin D Do Not Cut Risk for A-Fib
Neither marine omega-3 fatty acids, EPA and DHA, nor vitamin D3 are associated with a reduction in the risk for incident AF.
Benefits of Statin Use in Patients With AF
Treatment of patients with atrial fibrillation with statins was found to be associated with reduced all-cause and cardiovascular mortality.
Ablation for Atrial Fibrillation Beats Drug Therapy
For patients with atrial fibrillation, those undergoing ablation have a reduced risk for recurrent AF compared with those receiving drug therapy.
Serum VCAM-1 Levels and Incident Heart Failure
Higher serum levels of VCAM-1 may be associated with incident HFpEF.
FGF23 May Be Associated With Higher LV Mass, and Lower LA and LV Systolic Function
FGF23 levels may be associated with lower LV systolic function, higher LV mass, and lower LA function.
- Loading...
Loading...
Next post in AHA 2020
Loading... 
Loading...